<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zidovudine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zidovudine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zidovudine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10053" href="/d/html/10053.html" rel="external">see "Zidovudine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11909" href="/d/html/11909.html" rel="external">see "Zidovudine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708846"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prolonged use of zidovudine has been associated with symptomatic myopathy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis/severe hepatomegaly:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination, including with zidovudine and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F235151"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Retrovir</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868622"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ALTI-Zidovudine;</li>
<li>APO-Zidovudine;</li>
<li>Retrovir (AZT)</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056074"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462623"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c32c6c1-db7f-406e-9555-dcac726bead6">HIV perinatal transmission, prophylaxis or presumptive treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV perinatal transmission, prophylaxis or presumptive treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antiretroviral prophylaxis should begin as soon as possible after birth (preferably within 6 hours after delivery). Adjust dose throughout course as needed based on PNA and weight. Regimen choice and duration of therapy variable dependent on risk assessment and infant HIV NAT results. See "HIV-1 infection, treatment (confirmed infection)" if HIV infection is confirmed. See guidelines for additional information on risk stratification, specific strategy recommendations, and duration of therapy; the National Perinatal HIV hotline (1-888-448-8765) is a resource for expert consultation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Recommended zidovudine duration:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Preterm and term neonates born to persons </b>
<b>with only HIV-1:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Low risk of perinatal HIV transmission: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Preterm neonates: <b>Note: </b>Applicable to neonates who are not considered high risk.</p>
<p style="text-indent:-2em;margin-left:12em;">GA &lt;37 weeks: Zidovudine monotherapy prophylaxis: Continue for 4 to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:10em;">Term neonates: <b>Note: </b>Applicable to neonates born to a person with a viral load &lt;50 copies/mL at or after 36 weeks gestation and within 4 weeks of delivery:</p>
<p style="text-indent:-2em;margin-left:12em;">GA ≥37 weeks: Zidovudine monotherapy prophylaxis: May use zidovudine prophylaxis for 2 weeks if the neonate was born to a person who is currently receiving and has received at least 10 consecutive weeks of antiretroviral therapy (ART) during pregnancy, has been virally suppressed for the duration of pregnancy (≥2 consecutive HIV RNA tests &lt;50 copies/mL at least 4 weeks apart), did not have acute HIV infection during pregnancy, and has reported good ART adherence with no identified adherence concerns. Neonates who do not meet the above criteria should receive zidovudine monotherapy for 4 to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>High risk of perinatal HIV transmission</i>: <b>Note: </b>Applicable to neonates born to a person who did not receive antepartum ART or received only intrapartum ART, did not achieve viral suppression (≥2 consecutive HIV RNA tests &lt;50 copies/mL at least 4 weeks apart) within 4 weeks of delivery, or with acute HIV infection during pregnancy.</p>
<p style="text-indent:-2em;margin-left:10em;">Preterm and term neonates: Presumptive HIV therapy (3-drug regimen; also serves as prophylaxis): Continue 3-drug regimen appropriate for age for 2 to 6 weeks; if the 3-drug regimen is continued for &lt;6 weeks, zidovudine should be continued alone to complete 6 weeks of prophylaxis; see guidelines for additional details. <b>Note: </b> Optimal duration is unknown; duration varies based on infant HIV nucleic acid test results, maternal viral load at the time of delivery, and additional risk factors for HIV transmission; consult pediatric HIV expert to assess patient-specific risk factors and determine appropriate duration.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Preterm and term neonates born to persons with only</b>
<b> HIV-2:</b> Zidovudine monotherapy prophylaxis: Continue for 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Preterm and term neonates born to persons with both HIV-1 and HIV-2:</b> ARV regimen should be determined based on HIV-1 risk assessment.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<span style="text-decoration: underline">Oral</span>:</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;30 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;4 weeks: Oral: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 4 to 6 weeks: Oral: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 30 to &lt;35 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;2 weeks: Oral: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 2 to 6 weeks: Oral: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥35 weeks, PNA ≤6 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed dosing: Oral: 4 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed weight-band dosing:</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 kg: Oral: 10 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">3 to &lt;4 kg: Oral: 15 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to &lt;5 kg: Oral: 20 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">IV</span>: <b>Note:</b> The IV doses presented are 75% of the oral doses administered at the same interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>). Use IV route only until oral therapy can be administered.</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;30 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;4 weeks: IV: 1.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 4 to 6 weeks: IV: 2.25 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 30 to &lt;35 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;2 weeks: IV: 1.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≥2 to 6 weeks: IV: 2.25 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥35 weeks, PNA ≤6 weeks: IV: 3 mg/kg/dose every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment (confirmed infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-HHS.5'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=13007" target="_blank">https://hivdb.stanford.edu/</a> for more information). Treatment with ARV agents for documented HIV infection is lifelong. See infant HIV treatment dosing in "Dosing: Pediatric" when PMA ≥35 weeks, PNA ≥4 weeks, and weight is ≥4 kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">Oral</span>:</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;30 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;4 weeks: Oral: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 4 weeks to 8 to 10 weeks: Oral: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &gt;8 to 10 weeks: Oral: 12 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 30 to &lt;35 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;2 weeks: Oral: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≥2 weeks to 6 to 8 weeks: Oral: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &gt;6 to 8 weeks: Oral: 12 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥35 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;4 weeks:</p>
<p style="text-indent:-2em;margin-left:10em;">Weight-directed dosing: Oral: 4 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">Fixed weight-band dosing: Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">2 to &lt;3 kg: 10 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">3 to &lt;4 kg: 15 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">4 to &lt;5 kg: 20 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≥4 weeks: Oral: 12 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">IV</span>: <b>Note: </b>The IV doses presented are 75% of the oral doses administered at the same interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>). Use IV route only until oral therapy can be administered; use in combination with other antiretroviral agents.</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;30 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;4 weeks: IV: 1.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≥4 weeks to 8 to 10 weeks: IV: 2.25 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &gt;8 to 10 weeks: IV: 9 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 30 to &lt;35 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;2 weeks: IV: 1.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 2 weeks to 6 to 8 weeks: IV: 2.25 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &gt;6 to 8 weeks: IV: 9 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥35 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &lt;4 weeks: IV: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≥4 weeks: IV: 9 mg/kg/dose every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational (nonperinatal) postexposure prophylaxis (nPEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.6']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.6'])">Ref</a></span>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents. See infant nPEP dosing in "Dosing: Pediatric" when PMA ≥35 weeks, PNA ≥4 weeks, and weight is ≥4 kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Oral</span>:</p>
<p style="text-indent:-2em;margin-left:8em;">GA &lt;30 weeks:</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≤28 days: Oral: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≥29 days: Oral: 4 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GA 30 to &lt;35 weeks:</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≤14 days: Oral: 2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≥15 days: Oral: 4 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GA ≥35 weeks: Oral: 4 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">IV</span>:</p>
<p style="text-indent:-2em;margin-left:8em;">GA &lt;30 weeks:</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≤28 days: IV: 1.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≥29 days: IV: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GA 30 to &lt;35 weeks:</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≤14 days: IV: 1.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">PNA ≥15 days: IV: 3 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GA ≥35 weeks: IV: 3 mg/kg/dose every 12 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for hematologic toxicity:</b> Consider interruption of therapy for significant anemia (neonates: HgB &lt;7 g/dL) and/or significant neutropenia (neonates: ANC &lt;500 cells/mm<sup>3</sup>) until evidence of bone marrow recovery occurs; once bone marrow recovers, dose may be resumed using appropriate adjunctive therapy (eg, epoetin alfa); neonates with sustained abnormalities may need to discontinue or change antiretroviral drugs; duration of zidovudine can be limited in low-risk neonates; consult pediatric HIV specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-HHS.5','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-HHS.5','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F235179"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: </b>Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=13007" target="_blank">https://hivdb.stanford.edu/</a> for more information). Although described in some international product labeling, IV zidovudine dosing is not recommended for treatment of HIV as other ARVs are only available as oral products, and administration of an incomplete regimen (zidovudine monotherapy) is not recommended. IV zidovudine dosing may still be utilized for prophylaxis in neonates or during labor/delivery; see "Dosing: Neonatal" or "Dosing: Adult" (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-RetrovirCAN.1','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-RetrovirCAN.1','lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (PMA ≥35 weeks, PNA ≥4 weeks, and weight ≥4 kg), Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">4 to &lt;9 kg: Oral: 12 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">9 to &lt;30 kg: Oral: 9 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥30 kg: Oral: 300 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-directed dosing: Oral: 240 mg/<b>m<sup>2</sup></b>/dose every 12 hours, range: 180 to 240 mg/<b>m<sup>2</sup></b>/dose every 12 hours (maximum dose: 300 mg/dose).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational postexposure prophylaxis (nPEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.6']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.6'])">Ref</a></span>): Note: </b>Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (PMA ≥35 weeks and PNA ≥4 weeks of age) and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">4 to &lt;9 kg: Oral: 12 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">9 to &lt;30 kg: Oral: 9 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: Oral: 300 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 300 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for hematologic toxicity:</b> Consider interruption of therapy for significant anemia (Hgb &lt;7.5 g/dL or &gt;25% decrease from baseline) and/or significant neutropenia (ANC &lt;750 cells/mm<sup>3</sup> or &gt;50% decrease from baseline) until evidence of bone marrow recovery occurs; once bone marrow recovers, dose may be resumed using appropriate adjunctive therapy (eg, epoetin alfa); for persistent, severe anemia thought to be due to zidovudine, consider zidovudine discontinuation and implementation of a new regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F51193570"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants &gt;6 weeks, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): <b>Note:</b> Renally adjusted dose recommendations are based on oral doses of 160 mg/<b>m<sup>2</sup></b>/dose every 8 hours and IV dose of 120 mg/<b>m<sup>2</sup></b>/dose every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥10 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose every 8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis (IHD): Administer 50% of dose every 8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): Administer 50% of dose every 8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): No adjustment required</p></div>
<div class="block dohp drugH1Div" id="F51193571"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage reduction may be necessary due to extensive hepatic metabolism. Use with caution; closely monitor for hematologic toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F235156"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10053" href="/d/html/10053.html" rel="external">see "Zidovudine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients should receive IV therapy only until oral therapy can be administered.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33b6ae40-fec8-461f-9bf5-dbc9ea0f9b00">Perinatal HIV-1 transmission, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perinatal HIV-1 transmission, prevention:</b> Recommendations for use of intrapartum zidovudine are based on maternal HIV RNA levels assessed at 36 weeks' gestation or within 4 weeks of delivery, and other factors. Intrapartum zidovudine IV is recommended when HIV RNA is &gt;1,000 copies/mL or when the HIV RNA level is unknown near delivery. Intrapartum zidovudine IV should also be administered if a lack of adherence is suspected since the last RNA result or when HIV is initially diagnosed during labor. Patients with HIV RNA &gt;1,000 copies/mL should be given zidovudine even in cases of documented zidovudine resistance unless there is a history of hypersensitivity. Intrapartum zidovudine IV is not needed in patients receiving antiretroviral therapy (ART) who have HIV RNA &lt;50 copies/mL near delivery AND who are adherent to their ART regimen. If a fetal scalp electrode is needed during labor, consider the fetal risk of HIV transmission high even if maternal HIV RNA is &lt;50 copies/mL. The decision to administer zidovudine IV intrapartum to patients with HIV RNA ≥50 and ≤1,000 copies/mL near delivery should be made on a case-by-case basis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>During labor and delivery: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>
<b>:</b> Loading dose: 2 mg/kg over 1 hour followed by a continuous IV infusion of 1 mg/kg/hour until delivery (ie, clamping of the umbilical cord). For scheduled cesarean delivery, begin IV zidovudine at least 3 hours before surgery to provide dosing for a minimum of 3 hours. In cases of an urgent, unscheduled cesarean delivery due to maternal and fetal indications, consider administering the loading dose then proceeding to delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>). <b>Note:</b> Dosage based on total body weight.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily, in combination with other antiretroviral agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 mg/kg/dose every 4 hours around-the-clock (6 doses daily) in combination with other antiretroviral agents.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609f4b69-ac8d-490c-a393-00eea46d752e">HIV-1 nonoccupational postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 nonoccupational postexposure prophylaxis (nPEP) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not a component of the recommended antiretroviral regimen for patients with CrCl ≥60 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.6']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.6'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure and continue for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.6','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.6','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990836"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥15 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 100 mg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 1 mg/kg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease on intermittent hemodialysis:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 100 mg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 1 mg/kg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 100 mg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 1 mg/kg every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">CRRT: No adjustment needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988059"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied). However, adjustment may be necessary due to extensive hepatic metabolism. Closely monitor patients for hematologic toxicities.</p></div>
<div class="block adr drugH1Div" id="F235117"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages noted with oral administration in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (20%), nausea (51%), vomiting (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (neonates: 22%; adults: grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (63%), malaise (53%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (≥5%), abdominal pain (≥5%), constipation (6%), dyspepsia (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (9%), chills (≥5%), fatigue (≥5%), insomnia (≥5%), neuropathy (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≥5%), musculoskeletal pain (≥5%), myalgia (≥5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hepatic: Hyperbilirubinemia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (IV, including irritation at injection site, pain at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lipoatrophy</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy, chest pain, orthostatic hypotension (Loke 1990), syncope, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, dyschromia (including skin hyperpigmentation) (Premjith 2022), nail disease (changes in pigmentation including nail hyperpigmentation) (Chawre 2012, Premjith 2022), pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis (Murri 1996), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, increased lactate dehydrogenase, lactic acidosis (Mahto 2018), redistribution of body fat</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, dysphagia, flatulence, oral mucosa hyperpigmentation, oral mucosa ulcer, pancreatitis (including acute pancreatitis) (Mahto 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency, urinary hesitancy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia, pure red cell aplasia (Balakrishnan 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatomegaly with steatosis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immune reconstitution syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, confusion, decreased mental acuity, depression, dizziness, drowsiness, mania, pain, paresthesia, seizure, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (Murphy 1994), back pain, increased creatine phosphokinase in blood specimen, lipotrophy, muscle spasm, myopathy (Mahto 2018), myositis, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, macular edema, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, flu-like symptoms, rhinitis, sinusitis</p></div>
<div class="block coi drugH1Div" id="F235131"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Potentially life-threatening hypersensitivity to zidovudine or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Neutrophil count &lt;750/mm<sup>3</sup> or hemoglobin &lt;7.5 g/dL (4.65 mmol/L)</p></div>
<div class="block war drugH1Div" id="F235114"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Hematologic toxicity, including neutropenia and severe anemia have been reported with use, especially with advanced HIV-1 disease. Toxicity may be related to duration of use and prior bone marrow reserve. Hemoglobin reduction may occur in as early as 2 to 4 weeks; neutropenia usually occurs after 6 to 8 weeks. Pancytopenia has been reported (usually reversible). Use with caution in patients with bone marrow compromise (granulocytes &lt;1,000 cells/mm<sup>3</sup> or hemoglobin &lt;9.5 g/dL). Dose interruption may be required in patients who develop anemia or neutropenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipoatrophy: May cause loss of subcutaneous fat, especially in the face, limbs, and buttocks. Lipoatrophy incidence and severity are related to cumulative exposure and may be only partially reversible; improvement may take months to years after switching to a regimen that does not contain zidovudine. Monitor patients for signs of lipoatrophy and consider switching to a non-zidovudine-containing regimen if lipoatrophy occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Hematologic toxicity may be increased due to increased serum concentrations in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with CrCl &lt;15 mL/minute; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Latex is used in vial stopper. May cause allergic reactions in latex-sensitive individuals.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878674"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution in patients with ANC &lt;1,000 cells/mm<sup>3</sup> or Hgb &lt;9.5 g/dL; consider interruption of therapy for significant anemia (Hgb &lt;7.5 g/dL or reduction &gt;25% of baseline; neonates: Hgb &lt;7 g/dL or symptomatic) or neutropenia (ANC &lt;750 cells/mm<sup>3</sup> or reduction &gt;50% from baseline; neonates: ANC &lt;500 cells/mm<sup>3</sup>) (HHS [pediatric] 2023; manufacturer's labeling). If significant anemia or neutropenia occur during treatment of HIV, discontinue concomitant marrow-toxic medications if possible, and treat coexisting iron deficiency, opportunistic infections, and/or malignancies; persistent, severe anemia or neutropenia may require changing the antiretroviral regimen. If significant anemia occurs during therapy for perinatal HIV prophylaxis, consult with a pediatric HIV expert to determine if early discontinuation should be considered. Zidovudine-related adverse hematologic effects may be concentration-dependent and associated with increasing AUC (Fillekes 2014; HHS [pediatric] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse cardiac effects have been associated with zidovudine therapy. A prospective study of 325 pediatric patients aged 7 to 16 years with perinatally acquired HIV evaluated associations between previous or current antiretroviral agents and cardiac echocardiogram measures. When comparing patients currently receiving zidovudine (n=107) with those who were not, zidovudine therapy was associated with increased end-systolic wall stress and slightly larger heart size. Longer duration of zidovudine use was associated with higher wall stress (Williams 2018). A descriptive study evaluated 643 individuals 1 to 25 years of age with perinatally acquired HIV to determine prevalence of early cardiac dysfunction and reported that left ventricular ejection fraction was negatively associated with history of zidovudine exposure. Implications for cardiac outcomes later in life (eg, cardiomyopathy) are unknown (McCrary 2020; Williams 2018).</p></div>
<div class="block foc drugH1Div" id="F235125"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retrovir: 100 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retrovir: 10 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retrovir: 50 mg/5 mL (240 mL) [contains sodium benzoate; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (240 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p></div>
<div class="block geq drugH1Div" id="F235110"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F235134"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Retrovir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zidovudine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Retrovir Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $1.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Retrovir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $0.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zidovudine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $6.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868623"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retrovir (AZT): 100 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retrovir (AZT): 10 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retrovir (AZT): 10 mg/mL (240 mL) [contains sodium benzoate]</p></div>
<div class="block admp drugH1Div" id="F52614022"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals; use calibrated measuring device to accurately measure oral liquid dose; for neonatal patients, graduations of 0.1 mL are necessary due to small dose volumes.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV infusion: Administer over 1 hour; in neonates, dose may be infused over 30 minutes. Do not administer IM; do not administer IV push or by rapid infusion.</p></div>
<div class="block adm drugH1Div" id="F235128"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Avoid rapid infusion or bolus injection. Do not administer IM.</p>
<p style="text-indent:-2em;margin-left:4em;">Infuse over 1 hour; in pregnant patients, infuse loading dose over 1 hour followed by continuous infusion.</p></div>
<div class="block hazard drugH1Div" id="F49133417"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F235145"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Store undiluted vials at 15°C to 25°C (59°F to 77°F). Protect from light. When diluted in D5W, solution is physically and chemically stable for 24 hours at room temperature and 48 hours if refrigerated at 2°C to 8°C (36°F to 46°F). Attempt to administer diluted solution within 8 hours if stored at room temperature or 24 hours if refrigerated at 2°C to 8°C (36°F to 46°F) to minimize potential for microbial-contaminated solutions (vials are single-use and do not contain preservative).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets, capsules, syrup: Store at 15°C to 25°C (59°F to 77°F). Protect capsules from moisture.</p></div>
<div class="block usep drugH1Div" id="F53569507"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (Oral: FDA approved in ages ≥4 weeks and adults; Injection [short-term use]: FDA approved in adults); <b>Note:</b> HIV regimens consisting of three active antiretroviral agents from at least <b>two</b> classes are recommended; prevention of perinatal HIV-1 transmission (Oral, injection: FDA approved in ages 0 days to 6 weeks [postpartum therapy of HIV-1 exposed neonate] and adults [antepartum and intrapartum therapy of HIV-1 infected mother]); has also been used as HIV nonoccupational postexposure prophylaxis (nPEP).</p></div>
<div class="block mst drugH1Div" id="F235211"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Azidothymidine may be confused with azaTHIOprine, aztreonam</p>
<p style="text-indent:-2em;margin-left:4em;">Retrovir may be confused with acyclovir, ritonavir</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">AZT is an error-prone abbreviation (mistaken as azathioprine, aztreonam)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F235195"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor), OAT1/3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F235119"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for hematologic toxicity may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: Zidovudine may enhance the neutropenic effect of Amodiaquine.  Management: Avoid coadministration of zidovudine-containing antiretroviral therapy with amodiaquine when possible. If combined, monitor closely for neutropenia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Conventional) may diminish the therapeutic effect of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine due to the possibility of reduced zidovudine efficacy and increased myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine. Reduced efficacy of zidovudine is possible based on in vitro data. Also, increased myelosuppressive effects are possible with combined administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Oral Inhalation): Zidovudine may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Systemic): Zidovudine may enhance the adverse/toxic effect of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: Zidovudine may enhance the neutropenic effect of Trimethoprim. Trimethoprim may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49657801"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Contraception is not required to initiate or continue antiretroviral therapy.</p>
<p style="text-indent:0em;margin-top:2em;">The US department of Health and Human Services (HHS) perinatal HIV guidelines consider zidovudine an alternative nucleoside reverse transcriptase inhibitor for patients with HIV who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Optimization of the health of the person who will become pregnant is recommended. Selection of or changes to a specific antiretroviral regimen prior to pregnancy should be done as part of a shared decision-making process. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender-diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block pri drugH1Div" id="F235135"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Zidovudine has a high level of transfer across the human placenta; the placenta also metabolizes zidovudine to the active metabolite.</p>
<p style="text-indent:0em;margin-top:2em;">No increased risk of overall teratogenic effects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small-for-gestational-age infants. Actual risks may be influenced by maternal factors, such as disease severity, GA at initiation of therapy, and specific ART regimen; therefore, close fetal monitoring is recommended. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children not diagnosed with HIV but who were exposed to ART in utero or as a neonate and develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential metabolic dysfunction.</p>
<p style="text-indent:0em;margin-top:2em;">The US Department of Health and Human Services (HHS) perinatal HIV guidelines consider zidovudine an alternative nucleoside reverse transcriptase inhibitor for pregnant patients with HIV who are antiretroviral-naive, who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). In addition, patients who become pregnant while taking zidovudine may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of zidovudine are not significantly altered in pregnancy and dose adjustment is not needed.</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for use of intrapartum zidovudine are based on maternal HIV RNA levels assessed at 36 weeks' gestation or within 4 weeks of delivery, and other factors. Intrapartum zidovudine IV is recommended when HIV RNA is &gt;1,000 copies/mL or when the HIV RNA level is unknown near delivery. Intrapartum zidovudine IV should also be administered if a lack of adherence is suspected since the last RNA result or when HIV is initially diagnosed during labor. Patients with HIV RNA &gt;1,000 copies/mL should be given zidovudine even in cases of documented zidovudine resistance unless there is a history of hypersensitivity. Intrapartum zidovudine IV is not needed in patients receiving ART who have HIV RNA &lt;50 copies/mL within 4 weeks of delivery AND who are adherent to their ART regimen. If a fetal scalp electrode is needed during labor, consider the fetal risk of HIV transmission high even if maternal HIV RNA is &lt;50 copies/mL. The decision to administer zidovudine IV intrapartum to patients with HIV RNA ≥50 and ≤1,000 copies/mL within 4 weeks of delivery should be made on a case-by-case basis, and consider consistency in maintaining an undetectable viral load in the third trimester, compliance with prenatal care, or concerns with adherence.</p>
<p style="text-indent:0em;margin-top:2em;">ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of detection, and reduce the risk of perinatal transmission. Selection of or changes to a specific antiretroviral regimen during pregnancy should be done as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitoring of patients who are pregnant is more frequent than in patients who are not pregnant. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender-diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Health care providers should enroll all patients exposed to antiretroviral medications during pregnancy in the Antiretroviral Pregnancy Registry (1-800-258-4263). Enrollment should be done as early in pregnancy as possible.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for pregnant patients with HIV and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block mopp drugH1Div" id="F53569487"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=13007" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral drug-resistance testing is recommended before initiation of therapy in treatment-naive patients and before changing regimens in patients for whom treatment has failed. After initiation of or change in antiretroviral therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months (HHS [pediatric] 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Serum electrolytes (including anion gap), CBC and differential, SCr, and lipid profiles (baseline and periodically with therapy or if clinical presentation indicates need); serum lactate (if clinical presentation indicates need). For neonates and infants receiving zidovudine as presumptive HIV therapy, monitor Hgb and neutrophil counts (at baseline and, if therapy continues, 4 weeks after initiation) (HHS [perinatal] 2023).</p></div>
<div class="block pha drugH1Div" id="F235113"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Zidovudine is a thymidine analog which interferes with the HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication; nucleoside reverse transcriptase inhibitor</p></div>
<div class="block phk drugH1Div" id="F235130"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In general, pharmacokinetic data for pediatric patients &gt;3 months to 12 years of age are similar to data in adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Significant penetration into the CSF</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: 1 to 2.2 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">CSF/plasma ratio:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 3 months to Children 12 years (n=38): Median: 0.68; Range: 0.03 to 3.25</p>
<p style="text-indent:-2em;margin-left:6em;">Adults (n=39): Median: 0.6; Range: 0.04 to 2.62</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 25% to 38%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via glucuronidation to inactive metabolites, including GZDV; extensive first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Similar for tablets, capsules, and syrup</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &lt;14 days: 89%</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 14 days to 3 months: 61%</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 3 months to Children 12 years: 65%</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 64% ± 10%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal:</p>
<p style="text-indent:-2em;margin-left:4em;">Premature neonate: 6.3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Full-term neonates: 3.1 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 14 days to 3 months: 1.9 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 3 months to Children 12 years: 1.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.5 to 3 hours (mean 1.1 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 30 to 90 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Urine (72% to 74% as metabolites, 14% to 18% as unchanged drug)</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Urine (45% to 60% as metabolites, 18% to 29% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192016"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Cl is decreased, resulting in an increased half-life and AUC of zidovudine and major metabolite GZDV.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is decreased and plasma concentrations are increased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F235138"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Azoazol | Azotine | Crisazet | Enper | Exovir | Retrovir | Zetrotax | Zidovudina dosa | Zidovudina Filaxis | Zidovudina lando</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Farmanguinhos zidovudina | Lafepe zidovudina | Retrovir | Virozid | Zidovudina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Retrovir azt</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo Zidovudine | Zidohope</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Azaviral | Retrovir | Retrovir azt | Zidovudina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai jian | Apo Zidovudine | Fei te | Ke du | Na xin de | Pu xi ding | Qi luo ke | Retrovir | Zorpex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ciplazidovir | Retrovir | Retrovir azt | Zido h | Zidovudina | Zidovudina azt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Azitidin | Retrovir</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Zidovudin Aurobindo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lornox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Zidovudina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Zidovudina altan | Zidovudina combino pharm | Zidovudina G.E.S.</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Zido h</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Dovuvinex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Vick-Zidovudine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adovi | Retrovir | Reviral</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Viro Z | Zidine | Zido h | Zidohope | Zidomax | Zidovex | Zidovir | Zilion | Zydowin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aviro z | Retrovir | Zido h | Zidocos | Zidovir</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azidomine | Hawon zidobudine | Retrovir | Yuhan zidovudin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Zidovir</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Isadol | Retrovir | Retrovir azt | Timivudin | Zidic c | Zidovir | Zidovudina | Zidovudina protein</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Viro Z | Zidovex | Zidovir</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Zido h</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Retrocar | Retrovir | Zidovudina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Azovir | Retrovir</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Retrovir iv infusion</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Retrovir | Zidovudina | Zidovudina Aurobindo</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Zetrotax | Zidovudina icu vita</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Azidotimidin | Azimitem | Retrovir | Thymazid | Viro Z | Zido h | Zidovirine | Zidovirine azt | Zidovudin | Zidovudine avexima | Zidovudine azt | Zidovudine Ferein</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo Zidovudine | Retrovir</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo Zidovudine | Retrovir</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Antivir | Apo Zidovudine | Retrovir | T Za | T.o. vir | Zidis</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aviro z | Zido h</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Nardin | Retrovir | Zidovudinum</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Azt | AZT FU | Crisazet | Enper | Retrovir | Zidovudina | Zidovudina Filaxis</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Retrovir</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco zidovudine | Aspen Zidovudine | Auro Zidovudine | Cipla zidovudine | Dizovin | Dozra | Pharma Q Zidovudin | Pharma q zidovudine | Retrovir | Sonke zidovudine | Vari Zidovudine | Zidaid | Zidomat | Zidovir</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aspen Zidovudine | Aviro z | Retrovir | Zidine | Zido h | Zidovir</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Adco zidovudine | Aviro z | Retrovir | Zido h | Zidomat</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 82.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20871773">
<a name="20871773"></a>Balakrishnan A, Valsalan R, Sheshadri S, Pandit VR, Medep V, Agrawal RK. Zidovudine-induced reversible pure red cell aplasia. <i>Indian J Pharmacol</i>. 2010;42(3):189-191. doi:10.4103/0253-7613.66845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/20871773/pubmed" id="20871773" target="_blank">20871773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7667167">
<a name="7667167"></a>Bendayan R, Georgis W, and Rafi-Tari S, “Interaction of 3′-Azido-3′-Deoxythymidine With the Organic Base Transporter in a Cultured Renal Epithelium,” <i>Pharmacotherapy</i>, 1995, 15(3):338-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7667167/pubmed" id="7667167" target="_blank">7667167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9200638">
<a name="9200638"></a>Carpenter CC, Fischel MA, Hammer SM, et al, “Antiretroviral Therapy for HIV Infection in 1997. Updated Recommendations of the International AIDS Society - USA Panel,” <i>JAMA</i>, 1997, 277(24):1962-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/9200638/pubmed" id="9200638" target="_blank">9200638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS). Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>. Published April 18, 2016. Accessed July 11, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23248416">
<a name="23248416"></a>Chawre SM, Pore SM, Nandeshwar MB, Masood NM. Zidovudine-induced nail pigmentation in a 12-year-old boy. <i>Indian J Pharmacol</i>. 2012;44(6):801-802. doi:10.4103/0253-7613.103306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/23248416/pubmed" id="23248416" target="_blank">23248416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2663302">
<a name="2663302"></a>Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data. <i>Clin Pharmacokinet.</i> 1989;17(1):1-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/2663302/pubmed" id="2663302" target="_blank">2663302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7623605">
<a name="7623605"></a>D'Silva M, Leibowitz D, Flaherty JP. Seizure associated with zidovudine. <i>Lancet. </i>1995;346(8972):452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7623605/pubmed" id="7623605" target="_blank">7623605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736440">
<a name="24736440"></a>Fillekes Q, Kendall L, Kitaka S, et al. Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. <i>Pediatr Infect Dis J</i>. 2014;33(5):495-498. doi:10.1097/INF.0000000000000143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/24736440/pubmed" id="24736440" target="_blank">24736440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1970466">
<a name="1970466"></a>Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. <i>Ann Intern Med. </i>1990;112(10):727-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/1970466/pubmed" id="1970466" target="_blank">1970466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7760890">
<a name="7760890"></a>Gill PS, Harrington W, Kaplan MH, et al, “Treatment of Adult T-Cell Leukemia-Lymphoma With a Combination of Interferon Alfa and Zidovudine,” <i>N Engl J Med</i>, 1995, 332(26):1744-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7760890/pubmed" id="7760890" target="_blank">7760890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7832939">
<a name="7832939"></a>Gorman SE, Dela Cruz F, and Paloucek F, “Ketoconazole and Zidovudine Overdose,” <i>Am J Emerg Med</i>, 1995, 13(1):115-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7832939/pubmed" id="7832939" target="_blank">7832939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878246">
<a name="2878246"></a>Hagler DN, Frame PT. Azidothymidine neurotoxicity. <i>Lancet. </i>1986;2(8520):1392-1393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/2878246/pubmed" id="2878246" target="_blank">2878246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2900428">
<a name="2900428"></a>Hargreaves M, Fuller G, Costello C, Gazzard B. Zidovudine overdose. <i>Lancet</i>. 1988;27;2(8609):509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/2900428/pubmed" id="2900428" target="_blank">2900428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7760891">
<a name="7760891"></a>Hermine O, Bouscary D, Gessain A, et al, “Brief Report: Treatment of Adult T-Cell Leukemia-Lymphoma With Zidovudine and Interferon Alfa,” <i>N Engl J Med</i>, 1995, 332(26):1749-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7760891/pubmed" id="7760891" target="_blank">7760891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9853641">
<a name="9853641"></a>Hilts AE and Fish DN, “Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,” <i>Am J Health Syst Pharm</i>, 1998, 55:2528-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/9853641/pubmed" id="9853641" target="_blank">9853641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7574535">
<a name="7574535"></a>Hoggard PG, Veal GJ, Wild MJ, et al, “Drug Interactions With Zidovudine Phosphorylation <i>in vitro</i>,” <i>Antimicrob Agents Chemother</i>, 1995, 39(6):1376-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7574535/pubmed" id="7574535" target="_blank">7574535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7741372">
<a name="7741372"></a>Ioannidis JP, Cappelleri JC, Lau J, et al, “Early or Deferred Zidovudine Therapy in HIV-Infected Patients Without an AIDS-Defining Illness,” <i>Ann Intern Med</i>, 1995, 122(11):856-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7741372/pubmed" id="7741372" target="_blank">7741372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7616989">
<a name="7616989"></a>Kinloch-De Loes S, Hirschel BJ, Hoen B, et al, “A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection,” <i>N Engl J Med</i>, 1995, 333(7):408-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7616989/pubmed" id="7616989" target="_blank">7616989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," <i>Infect Control Hosp Epidemiol</i>, 2013, 34(9): 875-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2105796">
<a name="2105796"></a>Loke RH, Murray-Lyon IM, Carter GD. Postural hypotension related to zidovudine in a patient infected with HIV. <i>BMJ</i>. 1990;300(6718):163-164. doi:10.1136/bmj.300.6718.163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/2105796/pubmed" id="2105796" target="_blank">2105796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30505059">
<a name="30505059"></a>Mahto SK, Gupta PK, Taneja RS, Singh A. Zidovudine-induced lactic acidosis with acute pancreatitis and myopathy: lethal and rare complications. <i>Indian J Pharmacol</i>. 2018;50(4):212-214. doi:10.4103/ijp.IJP_285_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/30505059/pubmed" id="30505059" target="_blank">30505059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7479197">
<a name="7479197"></a>Marchbanks K, Dudley MN, Posner MR, et al, “Pharmacokinetics and Pharmacodynamics of High-Dose Zidovudine Administered as a Continuous Infusion in Patients With Cancer,” <i>Pharmacotherapy</i>, 1995, 15(4):451-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7479197/pubmed" id="7479197" target="_blank">7479197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794518">
<a name="31794518"></a>McCrary AW, Nyandiko WM, Ellis AM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. <i>AIDS</i>. 2020;34(4):539-548. doi:10.1097/QAD.0000000000002445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/31794518/pubmed" id="31794518" target="_blank">31794518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1503352">
<a name="1503352"></a>McLeod GX and Hammer SM, “Zidovudine: Five Years Later,” <i>Ann Intern Med</i>, 1992, 117(6):487-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/1503352/pubmed" id="1503352" target="_blank">1503352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8018300">
<a name="8018300"></a>Morris DJ, “Adverse Effects and Drug Interactions of Clinical Importance With Antiviral Drugs,” <i>Drug Saf</i>, 1994, 10(4):281-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/8018300/pubmed" id="8018300" target="_blank">8018300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1279153">
<a name="1279153"></a>Mueller BU, Jacobsen F, Butler KM, et al, “Combination Treatment With Azidothymidine and Granulocyte Colony-Stimulating Factor in Children With Human Immunodeficiency Virus Infection,” <i>J Pediatr</i>, 1992, 121(5 Pt 1):797-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/1279153/pubmed" id="1279153" target="_blank">1279153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8038679">
<a name="8038679"></a>Murphy D, Lynch M, Mulcahy F. Zidovudine related arthropathy. <i>BMJ</i>. 1994;309(6947):97. doi:10.1136/bmj.309.6947.97<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/8038679/pubmed" id="8038679" target="_blank">8038679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879796">
<a name="8879796"></a>Murri R, Antinori A, Camilli G, Zannoni G, Patriarca G. Fatal toxic epidermolysis induced by zidovudine. <i>Clin Infect Dis</i>. 1996;23(3):640-641. doi:10.1093/clinids/23.3.640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/8879796/pubmed" id="8879796" target="_blank">8879796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7646826">
<a name="7646826"></a>Newell ML and Gibb DM, “A Risk-Benefit Assessment of Zidovudine in the Prevention of Perinatal HIV Transmission,” <i>Drug Saf</i>, 1995, 12(4):274-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7646826/pubmed" id="7646826" target="_blank">7646826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36226018">
<a name="36226018"></a>Premjith R, Karthikeyan K. Zidovudine induced hyperpigmentation. <i>Indian Dermatol Online J</i>. 2022;13(3):398-399. doi:10.4103/idoj.idoj_449_21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/36226018/pubmed" id="36226018" target="_blank">36226018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at <a href="http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php" target="_blank">http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php</a>. Accessed December 30, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8481217">
<a name="8481217"></a>Rachlis A and Fanning MM, “Zidovudine Toxicity: Clinical Features and Management,” <i>Drug Saf</i>, 1993, 8(4):312-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/8481217/pubmed" id="8481217" target="_blank">8481217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retrovir.1">
<a name="Retrovir.1"></a>Retrovir (zidovudine) [prescribing information]. Durham, NC: ViiV Healthcare; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RetrovirCAN.1">
<a name="RetrovirCAN.1"></a>Retrovir (zidovudine) [product monograph]. Montreal, Quebec, Canada: ViiV Healthcare ULC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8094279">
<a name="8094279"></a>Skowron G, Bozzette SA, Lim L, et al, “Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients With AIDS or AIDS-Related Complex,” <i>Ann Intern Med</i>, 1993, 118(5):321-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/8094279/pubmed" id="8094279" target="_blank">8094279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2357867">
<a name="2357867"></a>Taburet AM, Naveau S, Zorza G, et al, “Pharmacokinetics of Zidovudine in Patients With Liver Cirrhosis,” <i>Clin Pharmacol Ther</i>, 1990, 47(6):731-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/2357867/pubmed" id="2357867" target="_blank">2357867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 10, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf" target="_blank">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated December 18, 2019. Accessed December 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/" target="_blank">https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0/</a>. Updated April 2020. Accessed June 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new</a>. Updated April 11, 2023. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated December 30, 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.6">
<a name="HHS.6"></a>US Department of Health and Human Services (HHS). Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. Available at <a href="https://stacks.cdc.gov/view/cdc/38856" target="_blank">https://stacks.cdc.gov/view/cdc/38856</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7616988">
<a name="7616988"></a>Volberding PA, Lagakos SW, Grimes JM, et al, “A Comparison of Immediate With Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults With CD4 Cell Counts of 500 or More Per Cubic Millimeter. AIDS Clinical Trials Group,” <i>N Engl J Med</i>, 1995, 333(7):401-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/7616988/pubmed" id="7616988" target="_blank">7616988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969115">
<a name="1969115"></a>Volberding PA, Lagakos SW, Koch MA, et al, “Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection. A Controlled Trial in Persons With Fewer Than 500 CD4-Positive Cells Per Cubic Millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases,” <i>N Engl J Med</i>, 1990, 322(14):941-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/1969115/pubmed" id="1969115" target="_blank">1969115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30102660">
<a name="30102660"></a>Williams PL, Correia K, Karalius B, et al. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. <i>AIDS</i>. 2018;32(16):2337‐2346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/30102660/pubmed" id="30102660" target="_blank">30102660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15614709">
<a name="15614709"></a>Wyles DL and Gerber JG, “Antiretroviral Drug Pharmacokinetics in Hepatitis with Hepatic Dysfunction,” <i>Clin Infect Dis</i>, 2005, 40(1):174-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/15614709/pubmed" id="15614709" target="_blank">15614709</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13007 Version 297.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
